CLINICAL CASE: USE OF CANAKINUMAB IN A PATIENT WITH SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS RESISTANT TO IMMUNOSUPPRESSANTS AND GENETICALLY ENGINEERED BIOPHARMACEUTICALS
https://doi.org/10.15690/pf.v11i2.965
Abstract
The article presents a case of successful use of an interleukin-1 monoclonal antibody drug (canakinumab) for severe systemic juvenile idiopathic arthritis refractory to treatment with classic immunosuppressants and genetically engineered biopharmaceuticals with a different mode of action. Canakinumab treatment shortly provided reduction in clinical and laboratory parameters of the disease activity, life quality improvement, development of an inactive disease stage and allowed reducing the prednisolone dose by 90% and avoiding intravenous and intraarticular administration of glucocorticoids.
About the Authors
E. I. Alexeeva
Scientific Center of Children’s Health, Moscow
Sechenov First Moscow State Medical University
Russian Federation
PhD, Professor, head of the SCCH rheumatology department, dean of the Faculty of Pediatrics at Sechenov First MSMU
Russian Federation
PhD, Professor, head of the SCCH rheumatology department, dean of the Faculty of Pediatrics at Sechenov First MSMU
R. V. Denisova
Scientific Center of Children’s Health, Moscow, Russian Federation
Russian Federation
Russian Federation
T. V. Sleptsova
Scientific Center of Children’s Health, Moscow, Russian Federation
Russian Federation
Russian Federation
T. M. Bzarova
Scientific Center of Children’s Health, Moscow, Russian Federation
Russian Federation
Russian Federation
K. B. Isaeva
Scientific Center of Children’s Health, Moscow, Russian Federation
Russian Federation
Russian Federation
E. V. Mitenko
Scientific Center of Children’s Health, Moscow, Russian Federation
Russian Federation
Russian Federation
E. G. Chistyakova
Scientific Center of Children’s Health, Moscow, Russian Federation
Sechenov First Moscow State Medical University, Russian Federation
Russian Federation
Russian Federation
A. M. Chomakhidze
Scientific Center of Children’s Health, Moscow, Russian Federation
Russian Federation
Russian Federation
N. I. Taybulatov
Scientific Center of Children’s Health, Moscow, Russian Federation
Russian Federation
Russian Federation
A. N. Fetisova
Scientific Center of Children’s Health, Moscow, Russian Federation
Russian Federation
Russian Federation
O. L. Lomakina
Scientific Center of Children’s Health, Moscow, Russian Federation
Russian Federation
Scientific Center of Children’s Health, Moscow, Russian Federation
Russian Federation
Scientific Center of Children’s Health, Moscow, Russian Federation
S. I. Valieva
Scientific Center of Children’s Health, Moscow, Russian Federation
Russian Federation
Russian Federation
References
1. Texbook of paediatric rheumatology. 6th Ed. J. Cassidy, R. Petty. Philadelphia, Saunders Elsevier, 2011.
2. Singh-Grewal D., Schneider R., Bayer N., Feldman B. M. Predictors of disease course and remission in systemic juvenile idiopathic arthritis: significance of early clinical and laboratory features. Arthritis Rheum. 2006; 54: 1595–1601.
3. Lomater C., Gerloni V., Gattinara M., Mazzotti J., Cimaz R., Fantini F. Systemic onset juvenile idiopathic arthritis: a retrospective study of 80 consecutive patients followed for 10 years. J. Rheumatol. 2000; 27: 491–496.
4. Namazova-Baranova L.S. Pediatricheskaya farmakologiya = Pediatric pharmacology. 2012; 9 (4): 15–24.
5. Pascual V., Allantaz F., Arce E., Punaro M., Banchereau J. Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J. Exp. Med. 2005; 201: 1479–86.
6. Atlas redkikh boleznei. Pod red. A.A. Baranova, L.S. Namazovoi-Baranovoi [Atlas of Rare Diseases. Edited by A.A. Baranov, L.S. Namazova-Baranova]. Moscow, Pediatr, 2013. 304 p.
7. Bzarova T.M., Alexeeva E.I., Peterkova V.A. Voprosy sovremennoi pediatrii = Current pediatrics. 2006; 5(5): 13–18.
8. Baranov A.A., Alexeeva E.I., Bzarova T.M., Valieva S.I., Denisova R.V., Isaeva K.B., Karagulyan N.A., Litvitskii P.F., Mitenko E.V., Sleptsova T.V., Fetisova A.N., Chistyakova E.G., Taibulatov N.I., Morev S.Yu. Voprosy sovremennoi pediatrii = Current pediatrics. 2013; 12 (1): 37–56.
9. Alexeeva E.I., Bzarova T.M., Semikina E.L., Akulova S.S. Voprosy sovremennoi pediatrii = Current pediatrics. 2006; 5 (6): 96–100.
10. Gattorno M., Pelagatti M. A., Meini A., Obici L., Barcellona R., Federici S. et al. Persistent efficacy of anakinra in patients with tumor necrosis factor receptor-associated periodic syndrome. Arthritis Rheum. 2008; 58: 1516–20.
11. Gattorno M., Piccini A., Lasiglie D., Tassi S., Brisca G., Carta S. et al. The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 2008; 58: 1505–1515.
12. Quartier P., Allantaz F., Cimaz R., Pillet P., Messiaen C., Bardin C. et al. A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial). Ann. Rheum. Dis. 2011; 70: 747–54.
13. Nigrovic P. A., Mannion M., Prince F. H., Zeft A., Rabinovich C. E., van Rossum M. A. et al. Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series. Arthritis Rheum. 2011; 63: 545–55.
14. Nicolino R., Pierre Q., Nico W. et al. A Phase II, Multicenter, Open-Label Study Evaluating Dosing and Preliminary Safety and Efficacy of Canakinumab in Systemic Juvenile Idiopathic Arthritis With Active Systemic Features. Arthritis & Rheumatism. 2012; 64 (2): 557–567.
15. Nicolino R., Hermine I., Brunner et al. Two Randomized Trials of Canakinumab in Systemic Juvenile Idiopathic Arthritis. N. Engl. J. Med. 2012; 367: 2396–406.
Review
For citations:
Alexeeva E.I., Denisova R.V., Sleptsova T.V., Bzarova T.M., Isaeva K.B., Mitenko E.V., Chistyakova E.G., Chomakhidze A.M., Taybulatov N.I., Fetisova A.N., Lomakina O.L., Valieva S.I. CLINICAL CASE: USE OF CANAKINUMAB IN A PATIENT WITH SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS RESISTANT TO IMMUNOSUPPRESSANTS AND GENETICALLY ENGINEERED BIOPHARMACEUTICALS. Pediatric pharmacology. 2014;11(2):88-94. https://doi.org/10.15690/pf.v11i2.965
Views:
685
Email this article 